脂肪基质细胞生物制品作为无细胞治疗方法:制造和治疗剂量决定体外功能。
Adipose stromal cells bioproducts as cell-free therapies: manufacturing and therapeutic dose determine in vitro functionality.
机构信息
Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service, Baden-Württemberg-Hessen, Friedrich-Ebert-Str.107, 68167, Mannheim, Germany.
出版信息
J Transl Med. 2023 Oct 16;21(1):723. doi: 10.1186/s12967-023-04602-9.
BACKGROUND
Extracellular vesicles (EV) are considered a cell-free alternative to mesenchymal stromal cell (MSC) therapy. Numerous reports describe the efficacy of EV in conferring immunomodulation and promoting angiogenesis, yet others report these activities to be conveyed in EV-free bioproducts. We hypothesized that this discrepancy may depend either on the method of isolation or rather the relative impact of the individual bioactive components within the MSC secretome.
METHODS
To answer this question, we performed an inter-laboratory study evaluating EV generated from adipose stromal cells (ASC) by either sequential ultracentrifugation (UC) or size-exclusion chromatography (SEC). The effect of both EV preparations on immunomodulation and angiogenesis in vitro was compared to that of the whole secretome and of the EV-free protein fraction after SEC isolation.
RESULTS
In the current study, neither the EV preparations, the secretome or the protein fraction were efficacious in inhibiting mitogen-driven T cell proliferation. However, EV generated by SEC stimulated macrophage phagocytic activity to a similar extent as the secretome. In turn, tube formation and wound healing were strongly promoted by the ASC secretome and protein fraction, but not by EV. Within the secretome/protein fraction, VEGF was identified as a potential driver of angiogenesis, and was absent in both EV preparations.
CONCLUSIONS
Our data indicate that the effects of ASC on immunomodulation and angiogenesis are EV-independent. Specific ASC-EV effects need to be dissected for their use as cell-free therapeutics.
背景
细胞外囊泡(EV)被认为是间充质基质细胞(MSC)治疗的无细胞替代物。许多报告描述了 EV 在赋予免疫调节和促进血管生成方面的功效,但其他报告则称这些活性是在无 EV 的生物制品中传递的。我们假设这种差异可能取决于分离方法,或者取决于 MSC 分泌组中各个生物活性成分的相对影响。
方法
为了回答这个问题,我们进行了一项实验室间研究,评估了通过顺序超速离心(UC)或大小排阻色谱(SEC)从脂肪基质细胞(ASC)产生的 EV。比较了这两种 EV 制剂对体外免疫调节和血管生成的影响,以及 SEC 分离后整个分泌组和无 EV 的蛋白质部分的影响。
结果
在本研究中,无论是 EV 制剂、分泌组还是无 EV 的蛋白质部分,都不能有效抑制有丝分裂原驱动的 T 细胞增殖。然而,SEC 产生的 EV 刺激巨噬细胞吞噬活性的程度与分泌组相似。相反,ASC 分泌组和蛋白质部分强烈促进了管形成和伤口愈合,但 EV 则没有。在分泌组/蛋白质部分中,VEGF 被鉴定为血管生成的潜在驱动因素,而在两种 EV 制剂中均不存在。
结论
我们的数据表明,ASC 对免疫调节和血管生成的影响与 EV 无关。需要对特定的 ASC-EV 作用进行剖析,以将其用作无细胞治疗剂。
相似文献
引用本文的文献
本文引用的文献
Int J Mol Sci. 2023-2-21
Stem Cells Int. 2021-1-16